Study among first to show drugs targeting the lung, rather than bacteria, may prevent staph infection in flu patients

Health News
Tags :
Health News
Share This :


Mount Sinai study among the first to show that drugs targeting the lung, rather than bacteria, may prevent staph infection in fl
Credit: Journal of Clinical Investigation (2023). DOI: 10.1172/JCI163402

Influenza infection (flu) is a major cause of death around the world, especially during years of flu pandemics. People who die of the flu often have a secondary lung infection with Staphylococcus aureus (staph) bacteria that starts a few days after flu infection begins. In new research, a team from Mount Sinai studied how the flu paves the way for staph infection in the lungs. Using mouse models, the researchers found that healthy lungs secrete liquid into their air sacs that prevents a staph infection. The flu blocks this liquid secretion by inhibiting a protein called CFTR, making it possible for staph that are inhaled into the air sacs to stick to the air sac walls, initiate infection, and damage the lungs. Treatment with a CFTR-activating drug, such as ivacaftor, restores liquid secretion in air sacs of the flu-infected lungs and restores the air sacs’ natural protection against staph infection.

The study is published in the Journal of Clinical Investigation.

The researchers applied a method to examine live air sacs of intact, perfused mouse lungs. Mice were untreated or intranasally instilled with the flu at 24 hours before lung imaging. The researchers used a pink dye to view air sac walls and a yellow solution to visualize the air sac liquid. In untreated lungs, loss of fluorescence of the yellow solution over time indicated that the solution was diluted by non-fluorescent liquid, which was secreted into the air sacs by cells that line the air sac walls. By contrast, in lungs infected with the flu, the yellow fluorescence was not lost, signaling that air sac walls failed to secrete liquid. Treatment of the air sac walls of flu-infected lungs with the CFTR-activating drug ivacaftor restarted the liquid secretion. Follow-up studies in mice co-infected with flu and staph showed that the loss of liquid secretion caused inhaled staph to stick to air sac walls, leading to staph infection, lung injury, and death.

The research uncovers how lung air sacs normally protect themselves against staph lung infection and reveals how flu disrupts that protection to make it easy for staph to cause secondary lung infection. The study also explores the possibility of giving ivacaftor to people with flu infection to prevent secondary staph infection, a deadly complication of the flu.

Researchers say these findings support a potential pathway for clinical trials that test whether ivacaftor can prevent secondary staph infection in people with the flu, which is highly feasible since the medication is already in clinical use for both children and adults and has a good record of safety and tolerability.

Speaking about the research, Mount Sinai’s Jaime Hook, MD said, “The combination of flu and staph infections in the lungs is deadly, particularly in young children and older people. Antibiotics don’t always resolve the staph infection because they might be started after the infection is already severe and it’s too late to treat it, or because the antibiotics don’t work if the bacteria are antibiotic-resistant. Our work shows, for the first time, how drugs that target the lung—rather than the bacteria—might treat staph infection in flu-infected lungs. We think that drugs that activate the CFTR protein, like ivacaftor, rescue a critical lung defense mechanism in flu-infected lungs to restore the lung‘s natural protection against staph infection. In this way, giving CFTR activator drugs to people with the flu who are at risk for a secondary staph infection might prevent staph infection from initiating, thereby preventing death from flu-staph coinfection.”

Study authors include Jaime Hook, MD, Assistant Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine), and Microbiology, at the Icahn School of Medicine at Mount Sinai; Stephanie Tang, Ph.D. Candidate in the Graduate School of Biomedical Sciences at Icahn Mount Sinai; and other co-authors. Researchers from Yale University School of Medicine and the Vagelos College of Physicians and Surgeons at Columbia University also contributed to the study.

More information:
Stephanie Tang et al, Rescue of alveolar wall liquid secretion blocks fatal lung injury by influenza-staphylococcal coinfection, Journal of Clinical Investigation (2023). DOI: 10.1172/JCI163402

Citation:
Study among first to show drugs targeting the lung, rather than bacteria, may prevent staph infection in flu patients (2023, August 15)
retrieved 15 August 2023
from https://medicalxpress.com/news/2023-08-drugs-lung-bacteria-staph-infection.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Popular News Posts

Categories

Our Exclusive Products

Our Store

Our mission is simple, offer quality products that make our customers lives better at a reasonable price, while ensuring a hassle-free shopping experience. This means that before we bring a product to market, we test it to ensure that it meets our high-level quality standards. Our customer service team understand our products and can answer most every product related question quickly and efficiently. We strive everyday to meet and exceed our customers’ expectations of quality and support! Should we ever fail to meet this expectation – contact us and we will make it right!

Our Value: We are proud of our product and accomplishments, but we typically don’t shout it from the rooftop. Instead, we prefer to let our product and customers do the talking. Our core values can be recognized in our product. The qualities we strive for include:

Pragmatism: We design simple, useful solutions for common needs
Quality: From design to final product, we strive for durable solutions that work
Originality: Creativity and innovation are what makes our product unique
Design: Our minimalist and bold design language focuses on functionality and simplicity that is timeless

0 +

Top Rated Products

0 +

Happy Customers